PRLD NASDAQ
Credit Risk of going bust: higher than 88% of companies Debt: 7.6% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down 99.3%), Prelude Therapeutics Incorporated would be worth roughly what it owes.
Total debt $17.6M against a stock market value of $214.2M.
Distance to default 1.88 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $2.8M (short-term plus half of long-term), stock volatility 165.0%; Altman Z'' -7.75. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Wilmington, DE 19805
US
Prelude Therapeutics, Inc. is a clinical-stage precision oncology company focused on identifying and developing innovative, targeted cancer treatments for patient populations with unmet medical needs. Its pipeline includes PRT543, currently undergoing Phase 1 clinical evaluation for certain solid tumors and myeloid malignancies. Another asset, PRT811, is also in Phase 1 trials, targeting various solid tumors, notably glioblastoma multiforme. The company is additionally progressing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a powerful and highly kinome-selective CDK9 inhibitor; PRT-SCA2, which is in preclinical development for several genomically selected cancers; PRT3645, a brain-penetrant molecule that precisely and effectively targets CDK4/6; and PRT-K4, another preclinical compound for solid tumors. Founded in 2016, the firm's headquarters are located in Wilmington, Delaware.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Babler Martin | A-Award | 38,000 | $3.94 | 2026-06-09 |
| Bonita David P | A-Award | 38,000 | $3.94 | 2026-06-09 |
| Sandor Victor | A-Award | 38,000 | $3.94 | 2026-06-09 |
| FRIEDMAN PAUL A | A-Award | 38,000 | $3.94 | 2026-06-09 |
| Dorton Katina | A-Award | 38,000 | $3.94 | 2026-06-09 |